Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

This study tests whether adding a drug called venetoclax to a standard intensive chemotherapy regimen improves outcomes for teenagers and adults newly diagnosed with a type of acute leukemia (ALL) that does not carry the Philadelphia chromosome mutation. **You may be eligible if...** - You are 14–60 years old - You have a new diagnosis of Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) - You have not received any prior treatment for this leukemia - You are in reasonably good health (ECOG 0–2) - Your liver, kidney, pancreas, and heart function meet the study requirements **You may NOT be eligible if...** - You have Burkitt lymphoma/leukemia or a mixed-lineage leukemia - You are pregnant or breastfeeding - You have poorly controlled diabetes (HbA1c above 7.5%) - You have a recent history of severe bleeding, blood clots, or active infections - You are HIV positive - You have a history of pancreatitis Talk to your doctor to see if this trial is right for you.